this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making
Age ≥18 years and ≤80 years;
Diagnosed with pulmonary hypertension (defined as mPAP >20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;
No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);
Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information;
Cardiac index (CI) < 1.5 L/min/m²;
Severe renal insufficiency (creatinine clearance rate (CrCL) < 30 mL/min);
Left ventricular ejection fraction (EF) <30% on echocardiography;
Severe hematological disease or severe bleeding tendency (platelet count <10×10⁹/L; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);